Scarica l'app Stockscreener
0.5701
3.94%
-0.0234
Dopo l'orario di chiusura:
.59
0.0199
+3.49%
Precedente Chiudi:
$0.5935
Aprire:
$0.6
Volume 24 ore:
943.18K
Relative Volume:
1.26
Capitalizzazione di mercato:
$33.70M
Reddito:
-
Utile/perdita netta:
$-41.95M
Rapporto P/E:
-0.1592
EPS:
-3.58
Flusso di cassa netto:
$-38.34M
1 W Prestazione:
-0.59%
1M Prestazione:
-10.36%
6M Prestazione:
-78.89%
1 anno Prestazione:
+6.16%
Intervallo 1D:
$0.57
$0.6025
Intervallo di 1 settimana:
$0.5451
$0.6098
Portata 52W:
$0.50
$5.8299
Elevation Oncology Inc Stock (ELEV) Company Profile
Nome
Elevation Oncology Inc
Settore
Industria
Telefono
(716) 371-1125
Indirizzo
101 FEDERAL STREET, BOSTON
Confronta ELEV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELEV
Elevation Oncology Inc
|
0.5701 | 33.70M | 0 | -41.95M | -38.34M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Elevation Oncology Inc Stock (ELEV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-05-30 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2021-12-23 | Iniziato | H.C. Wainwright | Buy |
Elevation Oncology Inc Borsa (ELEV) Ultime notizie
Items Tagged with 'ESMO IO 2024' - BioWorld Online
HC Wainwright Reiterates “Buy” Rating for Elevation Oncology (NASDAQ:ELEV) - Defense World
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2 - The Eastern Progress Online
Elevation Oncology nominates HER3 ADC as development candidate - BioWorld Online
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion - ShareCast
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference - The Eastern Progress Online
Elevation Oncology Inc licences Synaffix BV’s ADC platform - European Biotechnology News
Synaffix out-licenses ADC technology to Elevation Oncology - The Pharma Letter
Elevation Oncology selects EO-1022 as HER3 ADC candidate - Investing.com
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors - PR Newswire
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Eastern Progress Online
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 - PR Newswire
Elevation Oncology Shares Tumble 39% On $50 Mln Stock-And-Warran… - Marketscreener.com
ELEVElevation Oncology, Inc. Latest Stock News & Market Updates - StockTitan
Five things for pharma marketers to know for Friday morning - MM+M Online
433,545 Shares in Elevation Oncology, Inc. (NASDAQ:ELEV) Bought by GSA Capital Partners LLP - Defense World
Logos Global Management LP Adjusts Stake in Elevation Oncology I - GuruFocus.com
OrbiMed Advisors LLC Increases Stake in Elevation Oncology Inc - GuruFocus.com
Biotechnology Value Fund L P's Strategic Acquisition in Elevatio - GuruFocus.com
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readout - Investing.com
Goldman Sachs Group Inc's Strategic Acquisition in Elevation Onc - GuruFocus.com
Elevation Oncology’s Q3 2024 Highlights and Financial Report - TipRanks
Elevation Oncology's Cancer Drug Shows 43% Response Rate, Secures FDA Fast Track | ELEV Stock News - StockTitan
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements - PR Newswire
Ovarian Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Vanguard Group Inc's Strategic Acquisition in Elevation Oncology Inc - GuruFocus.com
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Zacks Investment Research
Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View - Yahoo Finance
Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart
AstraZeneca Receives CHMP's Approval for Wainzua in Europe - Zacks Investment Research
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Canada Finance
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - MSN
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review - MSN
Is Elevation Oncology Inc (ELEV) worth investing in despite its overvalued state? - US Post News
Trading Day Review: Elevation Oncology Inc (ELEV) Gains Momentum, Closing at 0.51 - The Dwinnex
It is Poised to be a Bull Market for Elevation Oncology Inc (ELEV) - SETE News
Elevation Oncology Inc (ELEV)’s stock price range in the last year - US Post News
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock - MSN
Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance
In the Green: Elevation Oncology Inc (ELEV) Closes at 0.52, Up/Down -3.69 from Previous Day - The Dwinnex
Taking on analysts’ expectations and winning: Elevation Oncology Inc (ELEV) - SETE News
Affimed Appoints New CEO, Shares Fall on Leadership Change - MSN
Market Momentum Report: Elevation Oncology Inc (ELEV)’s Positive Close at 0.59 - The Dwinnex
Elevation Oncology's SWOT analysis: promising ADC stock faces key data readouts - Investing.com
Should investors be concerned about Elevation Oncology Inc (ELEV)? - US Post News
Elevation Oncology Inc Azioni (ELEV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.76%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):